Datopotamab Deruxtecan Demonstrates Progression-Free Survival in Advanced Non-Small Cell Lung Cancer

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial &nbsp Positive high-level results from the TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 4.
  • textsms

Elevation Oncology Announces Pricing of $50 Million Public Offering

Elevation Oncology, a company focused on developing selective cancer therapies for solid tumors with significant unmet medical needs, has announced the pricing of an underwritten public offering of common stock and pre-funded warrants to purchase shares of common stock. The combined offering price is $2.2500 per share of common stock and accompanying warrant and $2.2499 per pre-funded warrant an..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms